Hodder Rebecca Kate, Freund Megan, Bowman Jenny, Wolfenden Luke, Campbell Elizabeth, Dray Julia, Lecathelinais Christophe, Oldmeadow Christopher, Attia John, Wiggers John
Hunter New England Population Health, Hunter New England Local Health District, Wallsend, New South Wales, Australia.
The University of Newcastle, Callaghan, New South Wales, Australia.
BMJ Open. 2017 Aug 18;7(8):e016060. doi: 10.1136/bmjopen-2017-016060.
Initiation of tobacco, alcohol and illicit substance use typically occurs during adolescence, with the school setting recommended to reduce adolescent substance use. Strengthening individual (eg, problem solving) and environmental (eg, caring relationships at school) resilience protective factors of adolescents has been suggested as a strategy for reducing substance use by adolescents; however, few studies have examined this potential. A study was conducted to investigate the effectiveness of a pragmatic school-based universal 'resilience' intervention in reducing the prevalence of tobacco, alcohol and illicit substance use, and increasing the individual and environmental protective factors of students.
A cluster-randomised controlled trial.
Thirty-two Australian secondary schools (20 intervention; 12 control).
Cohort of grade 7 students followed-up in grade 10 (2014; aged 15-16 years).
A pragmatic intervention involving school staff selection and implementation of available programmes and resources targeting individual and environmental 'resilience' protective factors for all grade 7-10 students was implemented in schools (2012-2014). School staff were provided implementation support.
An online survey collected baseline and follow-up data for primary outcomes: tobacco (ever, recent) and alcohol (ever, recent, 'risk') use, and secondary outcomes: marijuana and other illicit substance use, and individual (six-factor subscales, aggregate) and environmental (three-factor subscales, aggregate) protective factor scores. Generalised and linear mixed models examined follow-up differences between groups.
Follow-up data from 2105 students (intervention=1261; control=844; 69% of baseline cohort) were analysed. No significant differences were found between intervention and control students for any primary (ever tobacco: OR 1.25, 95% CI 0.92 to 1.68, p=0.14; recent tobacco: OR 1.39, 95% CI 0.84 to 2.31, p=0.19; recent ever alcohol: OR 1.11, 95% CI 0.83 to 1.48, p=0.46; alcohol: OR 1.13, 95% CI 0.78 to 1.62, p=0.51; 'risk' alcohol: OR 0.98, 95% CI 0.70 to 1.36, p=0.89) or secondary outcomes (marijuana: OR 1.12, 95% CI 0.74 to 1.68, p=0.57; other illicit substance: OR 1.19, 95% CI 0.67 to 2.10, p=0.54; individual protective factors: MD=0, 95% CI -0.07 to 0.06, p=0.89; environmental protective factors: MD: -0.02, 95% CI -0.09 to 0.06, p=0.65).
The universally implemented pragmatic school-based intervention was not effective in reducing the prevalence of tobacco, alcohol or illicit substance use, or in increasing the protective factors of students.
Australia and New Zealand Clinical Trials Register reference: ACTRN12611000606987.
青少年通常在青春期开始使用烟草、酒精和非法药物,建议利用学校环境来减少青少年的物质使用。有人提出,强化青少年的个人(如解决问题能力)和环境(如学校中的关爱关系)复原力保护因素是减少青少年物质使用的一种策略;然而,很少有研究探讨过这种可能性。本研究旨在调查一项基于学校的实用普遍性“复原力”干预措施在降低烟草、酒精和非法药物使用率以及提高学生个人和环境保护因素方面的有效性。
整群随机对照试验。
32所澳大利亚中学(20所干预学校;12所对照学校)。
对7年级学生队列进行跟踪随访至10年级(2014年;年龄15 - 16岁)。
在学校实施了一项实用干预措施(2012 - 2014年),该措施涉及学校工作人员挑选并实施针对所有7至10年级学生个人和环境“复原力”保护因素的现有项目和资源。为学校工作人员提供了实施支持。
通过在线调查收集基线和随访数据,主要结果包括:烟草使用(曾经使用、近期使用)和酒精使用(曾经使用、近期使用、“危险”使用),次要结果包括:大麻和其他非法药物使用,以及个人(六个因子分量表、总分)和环境(三个因子分量表、总分)保护因素得分。采用广义和线性混合模型检验组间随访差异。
对2105名学生的随访数据进行了分析(干预组 = 1261名;对照组 = 844名;占基线队列的69%)。干预组和对照组学生在任何主要结果(曾经使用烟草:比值比1.25,95%置信区间0.92至1.68,p = 0.14;近期使用烟草:比值比1.39,95%置信区间0.84至2.31,p = 0.19;近期曾经使用酒精:比值比1.11,95%置信区间0.83至1.48,p = 0.46;酒精使用:比值比1.13,95%置信区间0.78至1.62,p = 0.51;“危险”酒精使用:比值比0.98,95%置信区间0.70至1.36,p = 0.89)或次要结果(大麻:比值比1.12,95%置信区间0.74至1.68,p = 0.57;其他非法药物:比值比1.19,95%置信区间0.67至2.10,p = 0.54;个人保护因素:平均差 = 0,95%置信区间 - 0.07至0.06,p = 0.89;环境保护因素:平均差: - 0.02,95%置信区间 - 0.09至0.06,p = 0.65)方面均未发现显著差异。
普遍实施的基于学校的实用干预措施在降低烟草、酒精或非法药物使用率或提高学生保护因素方面无效。
澳大利亚和新西兰临床试验注册中心编号:ACTRN12611000606987。